Literature DB >> 9514797

Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study.

A Gadducci1, E Sartori, T Maggino, P Zola, F Landoni, A Fanucchi, N Palai, C Alessi, A M Ferrero, S Cosio, R Cristofani.   

Abstract

This multicenter retrospective study is based on 192 patients with advanced ovarian cancer in pathological complete response at second-look surgery. Ninety-four (48.9%) patients developed recurrent disease after a median time of 18 months (range, 4-89 months) from surgical reassessment. The recurrence involved the pelvis in 45 (47.9%) cases, the abdomen in 42 (44.7%), the retroperitoneal lymph nodes in 13 (13.8%), and distant sites in 20 (21.2%). On the whole series, 5- and 7-year disease-free survival rates after negative second-look were 47.4 and 44.5%, respectively. By log-rank test the disease-free survival rate was related to FIGO stage (P = 0.008), tumor grade (P = 0.0021), size of residual disease after initial surgery (P = 0.0038), and type of second-look (laparoscopy vs laparotomy, P = 0.0061), but not to histological type and first-line chemotherapy. Cox proportional hazard model showed that tumor grade, size of residual disease, and type of second-look were independent prognostic variables for disease-free survival. The risk ratio of relapse was 2.386 (95% CI, 1.140-4.990) for grade 2 and 3.118 (95% CI, 1.515-6.416) for grade 3 compared to grade 1 disease. For patients with residual disease 1-2 cm and > 2 cm the risk ratio was, respectively, 1.877 (95% CI, 1.117-3.156) and 2.156 (95% CI, 1.324-3.511) compared to patients with residual disease < 1 cm. The risk ratio was 1.826 (95% CI, 1.121-2.973) for patients who were submitted to a laparoscopic second-look compared to those who underwent a laparotomic reassessment. Poorly differentiated grade and large residual disease after initial surgery are the strongest prognostic variables for recurrence after a negative second-look.

Entities:  

Mesh:

Year:  1998        PMID: 9514797     DOI: 10.1006/gyno.1997.4890

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

Review 1.  Second-look laparotomy for epithelial ovarian cancer: a reappraisal.

Authors:  C S Chu; S C Rubin
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 2.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

3.  Feasibility and accuracy of second-look laparoscopy after gastrectomy for gastric cancer.

Authors:  Kentaro Inoue; Yasushi Nakane; Taku Michiura; Sou Yamaki; Rintaro Yui; Kazuhito Sakuramoto; Aiko Iwai; Katsuji Tokuhara; Yoshiro Araki; Songtae Kim; Koji Nakai; Mutsuya Sato; Keigo Yamamichi; A-Hon Kwon
Journal:  Surg Endosc       Date:  2009-01-30       Impact factor: 4.584

4.  In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer.

Authors:  Nate Larson; Sarah Roberts; Abhijit Ray; Brandon Buckway; Darwin L Cheney; Hamidreza Ghandehari
Journal:  Macromol Biosci       Date:  2014-09-04       Impact factor: 4.979

5.  Surgical second-look in epithelial ovarian cancer: high recurrence rate after negative results and lack of survival benefit limits its role in standard management.

Authors:  Salih Taşkın; Mete Güngör; Elif Aylin Taşkın; Fırat Ortaç
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

6.  The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Authors:  Nadim Bou Zgheib; Yin Xiong; Douglas C Marchion; Elona Bicaku; Hye Sook Chon; Xiaomang Ba Stickles; Entidhar Al Sawah; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Dung Tsa Chen; Johnathan M Lancaster
Journal:  Int J Oncol       Date:  2012-04-26       Impact factor: 5.650

Review 7.  The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.

Authors:  A E Selman; L J Copeland
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

8.  The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review.

Authors:  N B Rettenmaier; C R Rettenmaier; T Wojciechowski; L N Abaid; J V Brown; J P Micha; B H Goldstein
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

9.  Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.

Authors:  Yong Soon Kwon; Joo-Hyun Nam; Dae-Yeon Kim; Dae-Shik Suh; Jong-Hyeok Kim; Yong Man Kim; Young Tak Kim
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

10.  Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer.

Authors:  Sebastian Szubert; Dariusz Szpurek; Rafal Moszynski; Michal Nowicki; Andrzej Frankowski; Stefan Sajdak; Slawomir Michalak
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.